PD-(L)1 iNhibitors with concurrent IRadiation at VAried tumour sites in advanced Non-small cell lung cAncer

Trial details

Who runs it

Unicancer

Trial code

EU 2024-512173-27-00

Record updated

2025. november 3.

Original description

To compare Overall Survival (OS) rate between anti-PD-1 and chemotherapy versus anti-PD-1 and chemotherapy + radiotherapy with report of 1 year-rate.Read full original descriptionShow less

NIRVANA-Lung : PD-1 iNhibitor and chemotherapy with concurrent IRradiation at VAried tumour sites in advanced Non-small cell lung cAncer

To compare Overall Survival (OS) rate between anti-PD-1 and chemotherapy versus anti-PD-1 and chemotherapy + radiotherapy with report of 1 year-rate.

Inclusion: Patient must have signed a written informed consent form prior to any study specific procedures; Woman of childbearing potential and male patients must agree to use adequate contraception for the duration of study participation and up to 6 months after completing treatment/therapy; Patients affiliated to the social security system (or equivalent); Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits, and examinations including follow-up; Histologically or cytologically confirmed advanced (stage IIIB/IIIC/IV), squamous or non-squamous NSCLC; NSCLC patients eligible for treatment with pembrolizumab and chemotherapy according to the European Marketing Authorization: a. squamous: in combination with carboplatin and either paclitaxel or nab-paclitaxel ; b. non squamous with no EGFR or ALK positive mutations: in combination with pemetrexed and a platinum based chemotherapy; Patient ≥18 years of age; ECOG performance status 0 – 1; Life expectancy >3 months; Measurable lesion as assessed by RECIST version 1.1; Metastases and/or primary tumour eligible for 3 dimensional conventional radiotherapy (3D-CRT) or stereotactic ablative radiotherapy (SABR) in terms of dose constraints at organ at risk (according to QUANTEC review); Patients must have adequate organ function defined by the following laboratory results obtained within 14 days prior to the first study treatment: a. absolute neutrophil count of ≥1 500 /mm3, b. platelets ≥ 100 000/mm3, c. haemoglobin >9 g/dL (transfusions allowed), d. creatinine clearance >60 mL/min e. bilirubin ≤1.5 X ULN (unless Gilbert’s syndrome where 3 X ULN is permitted) f. serum ALT and AST ≤2.5 X ULN (unless documented liver metastasis where ≤5 X ULN is permitted) g. ALP ≤2.5 X ULN (unless documented bone or liver metastasis where ≤5X ULN is permitted). h. INR , PT, PTT ≤1.5 X ULN (unless the subject is receiving anticoagulant therapy).

Exclusion: Systemic immunosuppression or systemic immunosuppressive medicinal products within 2 weeks prior to study entry; Concomitant treatment with steroids > 10 mg; Patient who was administered a live, attenuated vaccine within 28 days prior to enrolment; Patient who have taken any investigational medicinal product or have used an investigational device within 30 days of inclusion; Stage IIIB/IIIC NSCLC patient eligible to curative (thoracic radiotherapy or surgery) treatments in first line treatment; Major surgery within the 28 days before initiating study treatment; Prior therapy with T-cell costimulation or checkpoint-targeted agents; Irradiation within 2 months before inclusion; Patient with evidence of active (presence of symptoms or requiring steroid treatment) central nervous system (CNS) metastases and/or carcinomatous meningitis. Patient with brain metastasis can be included if asymptomatic and not requiring steroids; Metastases located within 3 cm of the previously irradiated structures (EQD2doses): a. Spinal cord previously irradiated to >40 Gy; b. Brachial plexus previously irradiated to >50 Gy; c. Small intestine, large intestine, or stomach previously irradiated to >45 Gy; d. Brainstem previously irradiated to >50 Gy; e. Lung previously irradiated with prior V20Gy >30%; Symptomatic interstitial lung disease; Prior invasive malignancy within the past 2 years (except non-melanomatous skin cancer non-invasive carcinoma in-situ of the breast, oral cavity, bladder or cervix); Known Acquired Immune Deficiency Syndrome (AIDS) or severe uncontrolled co-morbidity; Known currently active infection including hepatitis B and hepatitis C; Patient with any other disease or illness that requires hospitalisation or is incompatible with the study treatment are not eligible. Patient unable to comply with study obligations for geographic, social, or physical reasons, or who is unable to understand the purpose and procedures of the study; Known hypersensitivity to one of the compounds or substances used in this protocol; Clinical need of radiotherapy (e.g.: whole brain irradiation, painful metastasis, bleeding, compressive metastases); Active autoimmune disease except vitiligo, type-1 diabetes, hypothyroid stabilized with hormonal substitution, psoriasis; Non-squamous NSCLC with targetable tumor mutations, activating EGFR mutations or ALK translocation; Pregnant or breast feeding woman; Person deprived of their liberty or under protective custody or guardianship; If pemetrexed: patient is unable or unwilling to take folic acid or vitamin B12 supplementation; Pre-existing peripheral neuropathy of a severity of grade ≥ 2 by NCI CTCAE v5.0; Leptomeningeal carcinomatosis, or metastases with indistinct borders making targeting not feasible.

EU CTIS 2024-512173-27-00